Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) shares saw unusually-strong trading volume on Wednesday . Approximately 625,600 shares changed hands during trading, an increase of 78% from the previous session's volume of 352,390 shares.The stock last traded at $9.02 and had previously closed at $9.40.
Wall Street Analyst Weigh In
Separately, BMO Capital Markets restated an "outperform" rating and set a $15.00 price target on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Centessa Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $10.00.
Check Out Our Latest Report on Centessa Pharmaceuticals
Centessa Pharmaceuticals Stock Up 0.6 %
The company has a current ratio of 8.00, a quick ratio of 8.00 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $948.93 million, a price-to-earnings ratio of -6.03 and a beta of 1.38. The firm's fifty day simple moving average is $10.93 and its two-hundred day simple moving average is $8.51.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Thursday, March 28th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. The firm had revenue of $6.85 million during the quarter. Sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.83 EPS for the current year.
Insider Buying and Selling at Centessa Pharmaceuticals
In other news, insider Karen M. Anderson sold 51,160 shares of the company's stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $11.88, for a total value of $607,780.80. Following the transaction, the insider now directly owns 71,525 shares in the company, valued at approximately $849,717. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Karen M. Anderson sold 51,160 shares of the company's stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $11.88, for a total value of $607,780.80. Following the transaction, the insider now directly owns 71,525 shares in the company, valued at approximately $849,717. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Harris Rotman sold 4,267 shares of the company's stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.10, for a total transaction of $34,562.70. Following the completion of the transaction, the senior vice president now owns 62,625 shares in the company, valued at $507,262.50. The disclosure for this sale can be found here. 11.54% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Centessa Pharmaceuticals
Several large investors have recently made changes to their positions in the stock. Octagon Capital Advisors LP increased its stake in Centessa Pharmaceuticals by 333.2% during the 4th quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company's stock worth $16,398,000 after buying an additional 1,584,500 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in Centessa Pharmaceuticals by 25.8% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company's stock worth $18,313,000 after buying an additional 580,500 shares during the period. Acuta Capital Partners LLC purchased a new stake in Centessa Pharmaceuticals during the 3rd quarter worth approximately $2,092,000. Franklin Resources Inc. increased its stake in Centessa Pharmaceuticals by 34.1% during the 4th quarter. Franklin Resources Inc. now owns 1,115,817 shares of the company's stock worth $8,882,000 after buying an additional 283,469 shares during the period. Finally, Platinum Investment Management Ltd. increased its stake in Centessa Pharmaceuticals by 96.7% during the 3rd quarter. Platinum Investment Management Ltd. now owns 337,544 shares of the company's stock worth $2,184,000 after buying an additional 165,919 shares during the period. 82.01% of the stock is currently owned by institutional investors and hedge funds.
Centessa Pharmaceuticals Company Profile
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.
Further Reading
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
